KYMR: KT-621's clinical progress positions it to transform oral therapy options in atopic dermatitis
The session highlighted advances in targeted protein degradation, with a focus on immunology and key programs like KT-621 (STAT6 degrader) and KT-579 (IRF5 degrader). KT-621 shows strong clinical promise for atopic dermatitis, aiming to expand the market for oral therapies, while robust trial desig…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.